People are panic about the exclusive right from competitor
in fact the most promising pharmaceutical share to look into it during this century however investor are overpanic on the news that their competitor getting exclusive right. However, you may overlook that Liquidia has actually obtain Hypertention Treatment Gains FDA approval which will definitelty become one of the most promising stock to look for year 2024. According to Raymond James, price target cap between $22 to $32 which means that buy the dip and earn beyond 100% in return for long term holding investor.
rebound in progress after slow recover from previous dip
hot stock to pick of the week
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
